Boehringer Ingelheim and Cipla forge partnership to co-market three oral anti-diabetic drugs
-
Partnership will help co-market three anti-diabetic drugs Oboravo®(Empagliflozin), Oboravo Met®(Empagliflozin+Metformin) and Tiptengio®(Empagliflozin+Linagliptin)
-
Empagliflozin has potential for addressing Cardiovascular disease (CVD) risk along with effective blood sugar control in eligible Indian patients with type 2 diabetes
-
Tiptengio has a strong blood sugar lowering effect and at the same time addresses multiple pathophysiological defects in type 2 diabetes
Mumbai, June 29, 2020 : Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla") and Boehringer Ingelheim India Pvt. Ltd. (BI) today announced their partnership in India to co-market three new oral anti-diabetics drugs Oboravo®(Empagliflozin), Oboravo Met®(Empagliflozin+Metformin) and Tiptengio®(Empagliflozin+Linagliptin)
Empagliflozin is approved for glucose-control in patients with type-2 diabetes; it is also approved for reducing the risk of cardiovascular death, in patients with type-2 diabetes and established cardiovascular disease. The Empagliflozin + Metformin combination Oboravo Met®can be given to newly diagnosed patients of type-2 diabetes who have higher baseline HbA1c levels.
The Empagliflozin + Linagliptin combination Tiptengio®is the world’s first approved combination of an SGLT-2 inhibitor and DPP4 inhibitor. In addition to a strong effect on lowering blood sugar levels, it also addresses multiple pathophysiological defects in type 2 diabetes, and is a big step towards improved management of type 2 diabetes. It will also help in reducing the pill burden for patients and help improve adherence to the prescribed treatment.
As per the International Diabetes Federation, India is home to 77 million adults aged between 20 and 79 years with diabetes, ranking second behind China; and is poised to 2 | 3
reach 134.2 million patients by 2045. Fortunately, while the number of patients is increasing, so is the awareness among the public to address it. The Indian diabetes market is valued at INR 1,45,451 million and is growing at 10.35% (IMS MAT May 2020) with the oral anti-diabetic market being valued at INR 1,07,354 million and growing at 11.34% (IMS MAT May 2020).
Commenting on the partnership, Nikhil Chopra, Executive Vice President & CEO - India Business, Cipla said, "We are committed to providing access to innovative medications that address unmet patient needs. Diabetes continues to be a focus area for Cipla and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access and reach capabilities, we will be at the forefront of providing holistic diabetes care."
Commenting on the expanded partnership, Mr. Sharad Tyagi, Managing Director - Boehringer Ingelheim India said, "We are excited about the expansion of our partnership with Cipla to provide pioneering medicines through the new oral anti-diabetics drugs. As a dedicated organization to the field of diabetes, we aim to provide wider access and innovative solutions to the medical fraternity and patients with one of the most comprehensive Diabetes portfolios in the country."
About Boehringer Ingelheim:
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
Since its inception in 2006, Boehringer Ingelheim in India has seen a high growth trajectory aided by the launches of innovator products like Pradaxa, Trajenta, Actilyse, Giotrif (local brand name Xovoltib), Ofev (local brand name Cyendiv), Glyxambi and Jardiance. 3 | 3
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at
www.boehringer-ingelheim.com or in our annual report:
http://annualreport.boehringer-ingelheim.com.
About Cipla:
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT May’20), 3rd largest in the pharma private market in South Africa (IQVIA MAT Mar’20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.